Diabetes Metab J.  2016 Aug;40(4):336-337. 10.4093/dmj.2016.40.4.336.

Response: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2016;40:240-7)

• Park S
• Park SY
• Rhee SY

• KMID: 2368522
• DOI: http://doi.org/10.4093/dmj.2016.40.4.336

Abstract

No abstract available.

MeSH Terms

Diabetes Mellitus, Type 2*
Humans

Figure

• 

  Fig. 1 Comparison of the diabetes bowel symptom questionnaire (DBSQ) scores between before and after rebamipide treatment according to dipeptidyl peptidase-4 inhibitor (DPP-4i) administration. Wilcoxon's signed rank test. Tx, treatment. aP<0.05, DPP-4i (–) group, bP<0.05, DPP-4i (+) group.

Reference

1. Park S, Park SY, Kim YJ, Hong SM, Chon S, Oh S, Woo JT, Kim SW, Kim YS, Rhee SY. Effects of rebamipide on gastrointestinal symptoms in patients with type 2 diabetes mellitus. Diabetes Metab J. 2016; 40:240–247.

2. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med. 2001; 161:1989–1996.

3. Arakawa T, Higuchi K, Fujiwara Y, Watanabe T, Tominaga K, Sasaki E, Oshitani N, Yoshikawa T, Tarnawski AS. 15th Anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005; 50:Suppl 1. S3–S11.

4. Talley NJ, Phillips SF, Melton J 3rd, Wiltgen C, Zinsmeister AR. A patient questionnaire to identify bowel disease. Ann Intern Med. 1989; 111:671–674.

5. Quan C, Talley NJ, Cross S, Jones M, Hammer J, Giles N, Horowitz M. Development and validation of the Diabetes Bowel Symptom Questionnaire. Aliment Pharmacol Ther. 2003; 17:1179–1187.